Biosimilars

Cobra Biologics moves to beef up mAb capacity

Cobra Biologics moves to beef up mAb capacity

By Gareth Macdonald

Corba Biologics has opted for a HyClone bioreactor to boost its antibody production capacity citing customer demand and biosimilars as the drivers for the investment.

Follow us

Products

View more

Webinars